FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295808029> ?p ?o ?g. }

• W4295808029 abstract "Although most acute promyelocytic leukemia(APL) with low-intermediate risk could survive the induction treatment, early death still a big problem to have effects on overall survival in real world.This study aimed to analyze the clinical characteristics and possible predictors of early death in newly diagnosed patients with low-intermediate-risk acute promyelocytic leukemia.Sixty patients with newly diagnosed low/intermediate-risk APL admitted to Mianyang Central Hospital from January 2013 to December 2021 were retrospectively analyzed.Sixty patients with a median age of 46 years (range, 17-75 years) were included. Fourteen patients (23.3%) were in low-risk group, and 46 patients (76.7%) were in intermediate-risk group. Fourteen patients (23.3%) died during induction treatment. Five patients died of hemorrhage, 5 of severe infection and 4 of differentiation syndrome. Multivariate analysis showed that HGB <65g/L at diagnosis (OR=38.474, 95%CI: 2.648~558.923, P=0.008) during induction treatment was an independent risk factors for early death in low- intermediate risk APL patients. In survival group, all patients achieved complete remission, the time to achieve remission was 25.87 ± 5.02 days, the average ATO dosage was 0.16 ± 0.03 mg/kg/day. In univariate analysis, there was no statistically significant difference in time span for remission when ATO dosage was in the 0.11~0.16mg/kg/day range. Compared with patients with low-risk APL, those with intermediate-risk APL had higher white blood cell counts (at diagnosis, day 3, day 5 and peak), higher level of lactate dehydrogenase, higher percentage of bone marrow promyelocytes, more platelet transfusions during treatment, and more early deaths (P<0.05). The overall survival of intermediate-risk APL patients seemed worse than those with low-risk APL (χ=5.033, P =0.025).In patients with low-intermediate risk APL, HGB <65g/L at diagnosis was an independent risk factors for early death. Remission could still be achieved at low-dose ATO without affecting the required time for low-intermediate risk APL patients. Differences in clinical characteristics were found between low-risk and intermediate-risk APL. The intermediate-risk group had higher early mortality risk than the low-risk group." @default.
• W4295808029 created "2022-09-15" @default.
• W4295808029 creator A5016572109 @default.
• W4295808029 creator A5017401112 @default.
• W4295808029 creator A5031232280 @default.
• W4295808029 creator A5039631951 @default.
• W4295808029 creator A5041542865 @default.
• W4295808029 creator A5062187564 @default.
• W4295808029 creator A5074014514 @default.
• W4295808029 creator A5086177424 @default.
• W4295808029 date "2022-09-14" @default.
• W4295808029 modified "2023-10-14" @default.
• W4295808029 title "Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia" @default.
• W4295808029 cites W1531493896 @default.
• W4295808029 cites W1982745688 @default.
• W4295808029 cites W2009774822 @default.
• W4295808029 cites W2036928147 @default.
• W4295808029 cites W2046657068 @default.
• W4295808029 cites W2057993974 @default.
• W4295808029 cites W2159507916 @default.
• W4295808029 cites W2166981346 @default.
• W4295808029 cites W2463809154 @default.
• W4295808029 cites W2774860131 @default.
• W4295808029 cites W2776538742 @default.
• W4295808029 cites W2803486846 @default.
• W4295808029 cites W2807311683 @default.
• W4295808029 cites W2810757164 @default.
• W4295808029 cites W2889901418 @default.
• W4295808029 cites W2905734723 @default.
• W4295808029 cites W2974370787 @default.
• W4295808029 cites W2991334718 @default.
• W4295808029 cites W2995798006 @default.
• W4295808029 cites W3045780792 @default.
• W4295808029 cites W3122553728 @default.
• W4295808029 cites W3126933831 @default.
• W4295808029 cites W3181613362 @default.
• W4295808029 cites W4293300006 @default.
• W4295808029 cites W4376595466 @default.
• W4295808029 doi "https://doi.org/10.3389/fonc.2022.895777" @default.
• W4295808029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36185183" @default.
• W4295808029 hasPublicationYear "2022" @default.
• W4295808029 type Work @default.
• W4295808029 citedByCount "2" @default.
• W4295808029 countsByYear W42958080292023 @default.
• W4295808029 crossrefType "journal-article" @default.
• W4295808029 hasAuthorship W4295808029A5016572109 @default.
• W4295808029 hasAuthorship W4295808029A5017401112 @default.
• W4295808029 hasAuthorship W4295808029A5031232280 @default.
• W4295808029 hasAuthorship W4295808029A5039631951 @default.
• W4295808029 hasAuthorship W4295808029A5041542865 @default.
• W4295808029 hasAuthorship W4295808029A5062187564 @default.
• W4295808029 hasAuthorship W4295808029A5074014514 @default.
• W4295808029 hasAuthorship W4295808029A5086177424 @default.
• W4295808029 hasBestOaLocation W42958080291 @default.
• W4295808029 hasConcept C104317684 @default.
• W4295808029 hasConcept C126322002 @default.
• W4295808029 hasConcept C141071460 @default.
• W4295808029 hasConcept C144301174 @default.
• W4295808029 hasConcept C185592680 @default.
• W4295808029 hasConcept C2776601000 @default.
• W4295808029 hasConcept C2778461978 @default.
• W4295808029 hasConcept C2778488018 @default.
• W4295808029 hasConcept C2781121885 @default.
• W4295808029 hasConcept C38180746 @default.
• W4295808029 hasConcept C55493867 @default.
• W4295808029 hasConcept C71924100 @default.
• W4295808029 hasConcept C90924648 @default.
• W4295808029 hasConceptScore W4295808029C104317684 @default.
• W4295808029 hasConceptScore W4295808029C126322002 @default.
• W4295808029 hasConceptScore W4295808029C141071460 @default.
• W4295808029 hasConceptScore W4295808029C144301174 @default.
• W4295808029 hasConceptScore W4295808029C185592680 @default.
• W4295808029 hasConceptScore W4295808029C2776601000 @default.
• W4295808029 hasConceptScore W4295808029C2778461978 @default.
• W4295808029 hasConceptScore W4295808029C2778488018 @default.
• W4295808029 hasConceptScore W4295808029C2781121885 @default.
• W4295808029 hasConceptScore W4295808029C38180746 @default.
• W4295808029 hasConceptScore W4295808029C55493867 @default.
• W4295808029 hasConceptScore W4295808029C71924100 @default.
• W4295808029 hasConceptScore W4295808029C90924648 @default.
• W4295808029 hasLocation W42958080291 @default.
• W4295808029 hasLocation W42958080292 @default.
• W4295808029 hasLocation W42958080293 @default.
• W4295808029 hasOpenAccess W4295808029 @default.
• W4295808029 hasPrimaryLocation W42958080291 @default.
• W4295808029 hasRelatedWork W1976044621 @default.
• W4295808029 hasRelatedWork W1979709008 @default.
• W4295808029 hasRelatedWork W2047870782 @default.
• W4295808029 hasRelatedWork W2120683327 @default.
• W4295808029 hasRelatedWork W2348689605 @default.
• W4295808029 hasRelatedWork W2461921748 @default.
• W4295808029 hasRelatedWork W2996549301 @default.
• W4295808029 hasRelatedWork W3028901598 @default.
• W4295808029 hasRelatedWork W3030103226 @default.
• W4295808029 hasRelatedWork W4295808029 @default.
• W4295808029 hasVolume "12" @default.
• W4295808029 isParatext "false" @default.
• W4295808029 isRetracted "false" @default.
• W4295808029 workType "article" @default.